PRLD compared with GERN: revenue, margins and what each company keeps, and the suppliers and customers both name

PRLDPrelude Therapeutics Inc

Mkt capRevenueRevenue

GERNGeron Corp

Mkt capRevenueRevenue

Compare

PRLDPrelude Therapeutics Inc

GERNGeron Corp

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

PRLDPrelude Therapeutics Inc

3.89· pre 3.89· delayed

Mkt cap$309.6MRevenue$6MQ2 FY26Revenue—

GERNGeron Corp

0.89· pre 0.89· delayed

Pre-marketOct 30 '26delayed

Mkt cap$574.6MRevenue$57MQ2 FY26Revenue$184MFY25

Compare

Pre-marketOct 30 '26delayed

PRLDPrelude Therapeutics Inc

GERNGeron Corp

3.89pre 3.89delayed

Price

0.89pre 0.89delayed

$309.6M

Mkt cap

$574.6M

Q2 FY26$6M

Revenue

$57MQ2 FY26

—

Revenue

$184MFY25

PRLD3.89vsGERN0.89Pre-marketOct 30 '26delayed

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

PRLD, solidGERN, dashed

Supply-chain overlap

Revenue flow

PRLD: latest quarter is a loss; flow not drawable. GERN: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only PRLD 3

INCYIncytecustomer

ABCLAbCellera Biologicscustomer

—Pathos AIunlistedcustomer

Shared 0

No shared counterparties.

Only GERN 2

—Tanner Pharmaunlistedsupplier

—Royalty Pharma Development Fundingunlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR